<DOC>
	<DOCNO>NCT02055131</DOCNO>
	<brief_summary>This prospective study consist test whether systematic use aspirin beneficial primary prevention vascular access hemodialysis attest doppler ultrasound exam . The investigator study aspirin resistance population patient undergoing hemodialysis . The investigator test sensibility resistant patient aspirin dose escalation . PFA-100 biologic test use study define aspirin resistance .</brief_summary>
	<brief_title>Antiaggregation Primary Prevention Vascular Access Hemodialysis</brief_title>
	<detailed_description>Three group dialyse patient include study . The first placebo group , second aspirin group fix dose last group include patient receive dose aspirin titrate result PFA-100 . At end study investigator able identify whether systematic antiaggregation suitable vascular access hemodialysis . The investigator also conclude good patient fix dose aspirin dose escalation determine result PFA-100 . The study analyse prevalence aspirin resistant patient particular population dialyse patient .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>dialysed patient vascular access age less one year serious complication vascular access previously hemorrhagic complication tight stenosis pregnant breastfeed woman patient receive baseline antiaggregant anticoagulant patient allow treated aspirin systolic blood pressure &gt; 200 mmhg diastolic blood pressure &gt; 115 mmhg liver failure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>vascular access</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>aspirin resistance</keyword>
	<keyword>PFA-100</keyword>
</DOC>